The latest report by IMARC Group, titled “Digital Dose Inhaler Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. The global digital dose inhaler market size reached US$ 2.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2028, exhibiting a growth rate (CAGR) of 14.6% during 2023-2028.

A digital dose inhaler, often referred to as a smart inhaler, is a cutting-edge medical device designed to improve the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Unlike traditional inhalers, digital dose inhalers are equipped with advanced sensors and connectivity features. These devices allow patients to track their inhaler usage and monitor their respiratory health more effectively. Digital dose inhalers record the date and time of each inhalation, providing patients with valuable data about their medication adherence. Additionally, some models can transmit this information to a companion mobile app or cloud platform, which can be accessed by healthcare providers for remote monitoring.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/digital-dose-inhaler-market/requestsample

Digital Dose Inhaler Market Trends and Drivers:

The increasing prevalence of respiratory conditions such as asthma and COPD is a primary driver of the digital dose inhaler market. As these conditions become more common, the demand for advanced inhaler solutions that offer precise dosing and monitoring capabilities is on the rise. Additionally, there is a growing emphasis on patient-centric healthcare, and digital dose inhalers align with this trend. Patients are increasingly seeking tools that empower them to actively manage their health, and digital inhalers offer a means to do so by facilitating self-monitoring and medication adherence. Other than this, the COVID-19 pandemic accelerated the adoption of telehealth and remote patient monitoring. Digital dose inhalers play a vital role in this context, allowing healthcare providers to remotely track patients’ inhaler use and adjust treatment plans as needed, thereby reducing in-person visits and improving overall care efficiency. Besides this, collaboration between pharmaceutical companies and inhaler device manufacturers is fueling innovation. Companies are investing in research and development to create more effective and user-friendly digital inhaler devices.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Type:

• Branded Medication
• Generics Medication

Breakup by Product:

• Metered Dose Inhaler
• Dry Powder Inhaler

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Competitive Landscape with Key Player:

• 3M Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Limited
• H&T Presspart Manufacturing Ltd.
• Koninklijke Philips N.V.
• Lupin Limited
• Novartis AG
• OPKO Health Inc.
• Propeller Health (ResMed)
• Sensirion AG Switzerland
• Teva Pharmaceutical Industries Ltd.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal